Page last updated: 2024-09-05

phosphatidylcholines and erlotinib hydrochloride

phosphatidylcholines has been researched along with erlotinib hydrochloride in 2 studies

Compound Research Comparison

Studies (phosphatidylcholines)	Trials (phosphatidylcholines)	Recent Studies (post-2010) (phosphatidylcholines)	Studies (erlotinib hydrochloride)	Trials (erlotinib hydrochloride)	Recent Studies (post-2010) (erlotinib hydrochloride)
32,204	443	5,593	4,353	786	3,033

Protein Interaction Comparison

Protein	Taxonomy	erlotinib hydrochloride (IC50)
Epidermal growth factor receptor	Homo sapiens (human)	0.1683
Receptor tyrosine-protein kinase erbB-2	Homo sapiens (human)	1.705
Serine/threonine-protein kinase B-raf	Mus musculus (house mouse)	0.04

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Balabathula, P; Mandal, B; Mittal, NK; Thoma, LA; Wood, GC	1
He, Y; Su, Z; Xu, H; Xue, L; Zhang, C	1

Other Studies

2 other study(ies) available for phosphatidylcholines and erlotinib hydrochloride

Article	Year
Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2016, Jan-01, Volume: 81 Topics: Antineoplastic Agents; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Microscopy, Electron, Transmission; Nanoparticles; Phosphatidylcholines; Phosphatidylethanolamines; Polyesters; Polyethylene Glycols; Protein Kinase Inhibitors; Tumor Stem Cell Assay	2016
Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy. Journal of controlled release : official journal of the Controlled Release Society, 2016, 05-10, Volume: 229 Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Benzoates; Carcinoma, Lewis Lung; Cell Survival; Doxorubicin; Drug Carriers; Drug Liberation; Drug Synergism; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Hydrogen-Ion Concentration; Male; Mice, Inbred C57BL; Nanoparticles; Phosphatidylcholines; Protein Kinase Inhibitors; Rats, Sprague-Dawley	2016

Article

Year

Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2016, Jan-01, Volume: 81

Topics: Antineoplastic Agents; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Drug Liberation; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Microscopy, Electron, Transmission; Nanoparticles; Phosphatidylcholines; Phosphatidylethanolamines; Polyesters; Polyethylene Glycols; Protein Kinase Inhibitors; Tumor Stem Cell Assay

2016

Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.

Journal of controlled release : official journal of the Controlled Release Society, 2016, 05-10, Volume: 229

Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Benzoates; Carcinoma, Lewis Lung; Cell Survival; Doxorubicin; Drug Carriers; Drug Liberation; Drug Synergism; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Hydrogen-Ion Concentration; Male; Mice, Inbred C57BL; Nanoparticles; Phosphatidylcholines; Protein Kinase Inhibitors; Rats, Sprague-Dawley

2016